Aurora Therapeutics, the first bespoke CRISPR startup, lays off staff and drops its PKU program as CEO Ed Kaye exits, months after a $16M seed round.
Aurora Therapeutics, the first company that focused on creating bespoke gene editing treatments, has laid off several staff members and stopped its lead program.
The …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The FDA, while promising flexibility in approving Baby KJ-type gene editing, still has set standards difficult for a small…
Lyora Therapeutics launches with $2.5M in pre-seed funding to revive stalled eye gene therapy programs from Editas and Biogen,…
ARPA-H taps 7 teams for up to $160M to build bespoke gene editing drugs, betting on Baby KJ's playbook — but some scientists say…
An ARPA-H program to jump-start custom gene editing treatments was delayed by a change in administrations. Now seven labs will…
The use of genome editing in early embryos has pulled back the curtain on the role of one of the key genes that orchestrates the…
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high…
